Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6S9Z5

UPID:
ZN474_HUMAN

ALTERNATIVE NAMES:
Testis-specific zinc finger protein

ALTERNATIVE UPACC:
Q6S9Z5; A8K4M0; Q96M07

BACKGROUND:
The Zinc finger protein 474, with alternative names such as Testis-specific zinc finger protein, is identified by the unique identifier Q6S9Z5. It is part of the zinc finger protein family, known for their role in DNA binding and the regulation of gene expression. The detailed functions and interactions of Zinc finger protein 474 in biological systems are subjects of ongoing research.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Zinc finger protein 474 holds promise for uncovering new therapeutic avenues. Given its potential role in the regulation of gene expression, insights into this protein could lead to innovative treatments for genetic disorders, highlighting its significance in the field of drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.